Search the Newsreel

The Campbell’s Company (CPB) Offers Promising Upside Despite Past Challenges

Brandes Investment Partners, an asset management company, released its second-quarter 2026 investor letter for its "Brandes Small Cap Value Fund". A copy of the letter is available to download here. In Q2 2026, the Fund underperformed the Russell 2000 Index's 21.49% gain and the …

Campbell's Chunky Frozen Bowls: 8 Flavors with Up to 28g Protein Launch in 2026 - News and Statistics

Campbell's Chunky is expanding into the frozen food market with eight new Chunky Frozen Bowls, each offering up to 28g of protein. This move addresses increased consumer demand for protein, partly driven by the growing use of GLP-1 weight-loss drugs. The strategy leverages an …

CAMP4 receives Australian clearance for SYNGAP1 therapy trial

CAMP4 Therapeutics Corporation has received clearance from Australia's Therapeutic Goods Administration to begin a Phase 1/2 clinical trial for CMP-002, a therapy for SYNGAP1-related disorder. This regulatory approval enables the company to secure an additional $50 million in a private placement, expanding its funding …

SYNGAP1 Disorder Has No Approved Treatments; CAMP4 Clears Trial

CAMP4 Therapeutics (Nasdaq: CAMP) has received regulatory clearance in Australia to begin a Phase 1/2 clinical trial for CMP-002, a potential first-in-class treatment for SYNGAP1-related disorder, for which there are currently no approved therapies. This clearance also allows CAMP4 to raise up to an …

CAMP4 Therapeutics Secures Australian Regulatory Clearance

CAMP4 Therapeutics has received regulatory clearance in Australia to begin a Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapeutic for SYNGAP1-related disorder. This clearance allows the company to open a clinical trial site in Australia and makes them eligible to receive an …

CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise

CAMP4 Therapeutics (CAMP) has received clearance from Australia's Therapeutic Goods Administration and a local Human Research Ethics Committee to begin a Phase 1/2 clinical trial for CMP-002, its investigational therapy for SYNGAP1-related disorder. This regulatory approval allows CAMP4 to proceed with human testing and …

CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of CAMP4 Therapeutics Corp (CAMP) regarding its dividend history and stock splits. It states that the company has not distributed any dividends over the past five years. The page also displays current stock price information and market performance data …

CAMP4 Therapeutics Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

CAMP4 Therapeutics Corp is a clinical-stage biopharmaceutical company focused on regulatory RNA-based therapies to upregulate gene expression for genetic diseases. The company is developing treatments for metabolic and central nervous system disorders, including CMP-CPS-001 for urea cycle disorders and CMP-SYNGAP for SYNGAP1-related disorders. It …

What You Need to Know Ahead of Campbell's Earnings Release

Campbell's (CPB) is expected to release its fiscal fourth-quarter earnings for 2026 soon, with analysts forecasting a profit of $0.40 per share, down 35.5% year-over-year. The company faces headwinds from cost pressures, high inflation expectations for fiscal 2027, and increased marketing spend, although it …

Campus Activewear Limited (NSE:CAMPUS) Looks Interesting, And It's About To Pay A Dividend

Camplify Holdings (ASX:CHL) Cuts Losses as Margin Strategy Takes Hold, but Growth and Funding Remain Key Tests

Campbell Soup stock trades steady as investors weigh fiscal 2024 earnings and margins

Campbell Soup stock is trading steadily as investors analyze the company's fiscal 2024 earnings, margin trends, and the balance between its Snacks and Meals & Beverages segments. The company reported net sales of approximately $9.0 billion for fiscal year 2024, a slight decline from …

CAMP4 Therapeutics Corp (CAMP) Balance Sheet

This article presents the quarterly and annual balance sheets for CAMP4 Therapeutics Corp (CAMP), allowing investors to evaluate its financial health. It details key financial metrics such as cash and investments, total assets, liabilities, and shareholders' equity, covering periods up to FY2026Q1. The data …

Camp4 Therapeutics secures TGA clearance for CMP-002, enabling up to $50.1M second closing

Camp4 Therapeutics has received Australian regulatory clearance from the TGA and local HREC to begin its Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder. This clearance triggered a financing milestone, making the company eligible to receive up to $50.1 million in additional proceeds from …

TradingKey

This article provides a detailed income statement for CAMP4 Therapeutics Corp (CAMP) covering quarterly and annual data from FY2023Q3 to FY2026Q1. It includes key financial metrics such as total revenue, operating expenses, operating profit, net income, and earnings per share. Additionally, the article features …

The Campbell's Company $CPB Shares Acquired by First Trust Advisors LP

First Trust Advisors LP has significantly increased its stake in The Campbell's Company (CPB) by 35% in Q1 2026, holding over 2.8 million shares valued at $62.8 million. This acquisition comes as Campbell's reported earnings of $0.50 per share, surpassing expectations, despite a 4.4% …

KBC Group NV Reduces Stake in The Campbell's Company $CPB

KBC Group NV significantly reduced its stake in The Campbell's Company (NYSE:CPB) by 38.9% in the first quarter, now owning 118,844 shares valued at $2.65 million. Despite this, other institutional investors like Koss Olinger Consulting LLC and Allspring Global Investments Holdings LLC increased their …

Campbell's swaps red labels for green on new soups

Campbell's is introducing a new line of five protein-rich soups with green-and-white labels, a significant change from their traditional red-and-white design used for over 125 years. This shift aims to capitalize on the growing consumer demand for high-protein foods, with the new soups featuring …

Is Campbell’s (CPB) New Protein Soup Line a Real Shift in Its Wellness Strategy?

Campbell's recently launched a new line of Protein Soups, featuring bone broth and 20 grams of protein per can, targeting health-conscious consumers. This initiative, alongside a gluten-free condensed soup partnership, aligns with a focus on health-oriented innovation to counter volume stagnation in traditional products. …

Campus Activewear revenue rises 11.4%, PAT up 23.8% in FY26

Camping World (NYSE:CWH) Stock Price Down 5.8% - Time to Sell?

Campbell’s launches protein soups with bone broth

The Campbell's Co. has launched a new line of protein-centric canned soups featuring a bone broth base and 20 grams of protein per can. Available in five varieties, these soups aim to meet consumer demand for nutritious and satisfying food options. They can be …

Campbell's Cream of Mushroom by Campbell Soup Company - pantry classic still shapes a billion-dollar segment

Campbell's Cream of Mushroom, a product of Campbell Soup Company (COF), is highlighted not just as a soup but as a crucial, multi-use cooking ingredient that underpins a billion-dollar segment within the company's Meals & Beverages portfolio. The article delves into its enduring market …

Camping World (CWH) to Post Earnings on Wednesday

Camplify Holdings (ASX: CHL) Shares Sink — Is This Brutal Sell-Off a Warning or an Opportunity?

Campbell’s Announces ‘No Artificial Meat’ in New Soup Line After Executive Scandal

Campbell's is launching a new "High Quality Ingredients" soup line with "no artificial meat" prominently displayed on its packaging. This move comes in response to public scrutiny following a former executive's controversial claims about the company using "bioengineered meat" and 3D-printed chicken. Campbell’s vehemently …

Campbell Soup stock stays anchored by 2025 sales and margin data

Campbell Soup's stock valuation is anchored by its reported fiscal 2025 financial figures, including $9.6 billion in net sales, $2.97 adjusted EPS, $1.4 billion adjusted EBIT, and a 4.2% adjusted EBIT margin. These numbers provide a clear benchmark for investors, demonstrating the company's earnings …

Updated: Campbell’s Cooks Up New High-Protein Soup Lineup Packing 20g of Protein Per Can

The Campbell's Company has launched a new line of Campbell's® Protein Soups, offering 20 grams of protein and a good source of fiber per can. This innovation responds to consumer demand for nutrient-dense and convenient meals, with over 71% of Americans actively seeking more …

The Campbell’s Co. delivers protein-packed soups

The Campbell's Co. is launching a new line of protein-rich canned soups, each featuring a bone broth base and 20 grams of protein. These soups, available in five varieties, aim to meet consumer demand for flavorful and nutritious food options. The products can be …

Campbell’s Launches 'No Artificial Meat' Soup Line Following Backlash Over Executive’s Past Claims

Campbell's has introduced a new "High Quality Ingredients" soup line, prominently featuring "no artificial meat" labeling. This initiative follows a 2025 controversy where a former executive's leaked comments criticized Campbell's products, claiming they contained "bioengineered meat." The company aims to restore consumer trust and …

Campbell’s Debuts High-Protein Soup Line With “No Artificial Meat” Claims

The Campbell Soup Company has launched a new "High Quality Ingredients" soup line, explicitly marketed with "no artificial meat" claims, following public outcry and a boycott over viral allegations of synthetic ingredients. This move aims to restore consumer trust after a former executive's leaked …

Campbell Soup stock trades steady as margins and snacks drive earnings resilience

Campbell Soup stock demonstrates resilience through stable margins and growth in its snacks segment, despite some pressure in meals and beverages. The company reported increased adjusted EPS in fiscal 2025 due to strong pricing and cost control, with its snacks division contributing significantly to …

Campbell's Builds Protein Platform with New Soup Line

Campbell's has launched a new line of Protein Soups, featuring five varieties that deliver 20g of protein per can. These soups are made with ingredients like bone broth, white meat chicken, quinoa, beans, and lentils, catering to the growing consumer demand for convenient, protein-rich …

Campbell Soup stock trades steady as investors weigh margins and snacks growth

Campbell Soup stock is trading steadily as investors assess the balance between stable food demand and margin-focused execution. Recent quarterly results highlighted growth in the snacks segment and effective cost discipline, with the company maintaining a cautious full-year outlook. The stock provides defensive food …

The Campbell's Company (NASDAQ:CPB) Receives Consensus Rating of "Reduce" from Analysts

The Campbell's Company (NASDAQ:CPB) has received a consensus "Reduce" rating from analysts, with eight sell and twelve hold recommendations. The average 12-month price target is approximately $21.88, while the stock recently traded lower at $22.08. Despite the cautious analyst outlook and recent trading performance, …

The Campbell's Cream of Mushroom - Campbell Soup Company bets on steady pantry demand

Campbell's Cream of Mushroom soup remains a core product for Campbell Soup Company, serving as a staple in North American kitchens for both consumption and as a versatile cooking ingredient. Despite competitive pressures from private labels and calls for healthier options, Campbell's leverages its …